Karuna Therapeutics, Inc. clinical trials

Acquired by Bristol-Myers Squibb, Mar 18, 2024 · source ↗

The registry lists 23 studies whose lead sponsor is Karuna Therapeutics, Inc.. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. All Bristol-Myers Squibb studies →

• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)RecruitingNCT06126224Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RecruitingNCT05980949Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersRecruitingNCT07681076Phase 4

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingNCT07424404Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingNCT07204418Phase 1

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingNCT07686263Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)RecruitingNCT06585787Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)RecruitingNCT05511363Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05304767Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and DigoxinCompletedNCT07118215Phase 1

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• KarXT Concentrations in the Breast Milk and Plasma of Lactating FemalesCompletedNCT07257120Phase 4

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaCompletedNCT06572449Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaCompletedNCT05145413Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy ParticipantsCompletedNCT06729970Phase 1

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaCompletedNCT05919823Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)CompletedNCT04820309Phase 3

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted before Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult ParticipantsCompletedNCT06605950Phase 1

  Sponsor listed in the registry: Karuna Therapeutics, Inc., a Bristol Myers Squibb company · First submitted after Karuna Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)CompletedNCT04738123Phase 3

  Sponsor listed in the registry: Karuna Therapeutics · First submitted before Karuna Therapeutics became part of Bristol-Myers Squibb

• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)CompletedNCT04659174Phase 3

  Sponsor listed in the registry: Karuna Therapeutics · First submitted before Karuna Therapeutics became part of Bristol-Myers Squibb

• An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of SchizophreniaTerminatedNCT05643170Phase 3

  Sponsor listed in the registry: Karuna Therapeutics · First submitted before Karuna Therapeutics became part of Bristol-Myers Squibb

• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)CompletedNCT04659161Phase 3

  Sponsor listed in the registry: Karuna Therapeutics · First submitted before Karuna Therapeutics became part of Bristol-Myers Squibb

• A Study to Assess Safety and Efficacy of KarXT in Adult Patients With SchizophreniaCompletedNCT03697252Phase 2

  Sponsor listed in the registry: Karuna Therapeutics · First submitted before Karuna Therapeutics became part of Bristol-Myers Squibb

• Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus TrospiumCompletedNCT02831231Phase 1

  Sponsor listed in the registry: Karuna Therapeutics · First submitted before Karuna Therapeutics became part of Bristol-Myers Squibb